Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2

The present exploratory analysis examined the efficacy, safety, and quality-of-life effects of everolimus (EVE) + exemestane (EXE) in the subgroup of patients in BOLERO-2 whose last treatment before study entry was in the (neo)adjuvant setting. In BOLERO-2, patients with hormone-receptor-positive (H...

詳細記述

保存先:
書誌詳細
主要な著者: Beck, J. Thaddeus, Hortobagyi, Gabriel N., Campone, Mario, Lebrun, Fabienne, Deleu, Ines, Rugo, Hope S., Pistilli, Barbara, Masuda, Norikazu, Hart, Lowell, Melichar, Bohuslav, Dakhil, Shaker, Geberth, Matthias, Nunzi, Martina, Heng, Daniel Y. C., Brechenmacher, Thomas, El-Hashimy, Mona, Douma, Shyanne, Ringeisen, Francois, Piccart, Martine
フォーマット: Artigo
言語:Inglês
出版事項: Springer US 2013
主題:
Clinical Trial
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3907668/
https://ncbi.nlm.nih.gov/pubmed/24362951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2814-5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料